We are live on ! Find out more
SB

Samsara BioCapital Portfolio holdings

AUM $1.03B
1-Year Est. Return 214.94%
This Fund
S&P 500
This Quarter Est. Return
-21.88%
1 Year Est. Return
+214.94%
3 Year Est. Return
+1,814.37%
5 Year Est. Return
+1,842.35%
10 Year Est. Return
–
AUM
$397M
AUM Growth
-$118M
Cap. Flow
+$42.4M
Cap. Flow %
10.67%
Top 10 Hldgs %
64.21%
Holding
58
New
7
Increased
4
Reduced
4
Closed
1

Top Buys

Rank Stock Value
1
ACLX
Arcellx
ACLX
+$16.7M
2
ZYME icon
Zymeworks
ZYME
+$8.65M
3
SRRK icon
Scholar Rock
SRRK
+$5.8M
4
ALXO icon
ALX Oncology
ALXO
+$4.49M
5
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$4.08M

Top Sells

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$4.64M
2
SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
+$518K
3
NKTX icon
Nkarta
NKTX
+$11

Sector Composition

Rank Sector Weight
1 Healthcare 97.57%
2 Financials 2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IGMS
26
DELISTED
IGM Biosciences
IGMS
$4.13M 1.04%
+154,664
New +$2.88M
RYTM icon
27
Rhythm Pharmaceuticals
RYTM
$7.96B
$3.98M 1%
345,293
– –
RXRX icon
28
Recursion Pharmaceuticals
RXRX
$1.73B
$3.86M 0.97%
539,236
– –
VIRX
29
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$3.38M 0.85%
711,039
– –
SWTX
30
DELISTED
SpringWorks Therapeutics
SWTX
$3.34M 0.84%
59,204
-81,063
-58% -$4.64M
ALBO
31
DELISTED
Albireo Pharma Inc
ALBO
$2.98M 0.75%
100,000
– –
BLSA
32
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$2.96M 0.75%
300,000
– –
BOLT icon
33
Bolt Biotherapeutics
BOLT
$7.78M
$2.88M 0.72%
52,458
+15,585
+42% +$1.05M
DBTX
34
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
$2.51M 0.63%
826,422
– –
ELEV
35
DELISTED
Elevation Oncology
ELEV
$2.35M 0.59%
932,240
– –
AMYT
36
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
$2.31M 0.58%
+279,715
New +$2.52M
SYRS
37
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$2.26M 0.57%
189,962
-28,958
-13% -$518K
SYRE icon
38
Spyre Therapeutics
SYRE
$9.25B
$2.03M 0.51%
35,349
– –
DAWN
39
DELISTED
Day One Biopharmaceuticals
DAWN
$2.01M 0.51%
202,500
– –
NVAX icon
40
Novavax
NVAX
$1.31B
$2M 0.5%
27,144
– –
EQ icon
41
Equillium
EQ
$133M
$1.94M 0.49%
615,541
– –
NVAX icon
42
CALL
Novavax
NVAX
$1.31B
$1.72M 0.43%
23,400
-59,200
-72% -$5.28M
BCEL
43
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$1.26M 0.32%
396,835
– –
VTVT icon
44
vTv Therapeutics
VTVT
$139M
$1.18M 0.3%
40,888
– –
ALLK
45
DELISTED
Allakos
ALLK
$981K 0.25%
172,089
– –
ODT
46
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$925K 0.23%
700,421
– –
SRZN icon
47
Surrozen
SRZN
$301M
$903K 0.23%
20,000
– –
TERN
48
DELISTED
Terns Pharmaceuticals
TERN
$859K 0.22%
289,068
– –
KALA icon
49
KALA BIO
KALA
$14.5M
$830K 0.21%
241
– –
BNTX icon
50
BioNTech
BNTX
$23.5B
$688K 0.17%
4,031
– –
1
2
3

Similar funds

MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
WHCM
Wolf Hill Capital Management Greenwich, Connecticut $1.03B AUM 80.44% 1-Year Est. Return
JSC
J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return
IAS
IMA Advisory Services Denver, Colorado $1.02B AUM 18.66% 1-Year Est. Return
CM
Condire Management Dallas, Texas $1.03B AUM 162.78% 1-Year Est. Return
CFFNO
Common Fund For Nonprofit Organizations Wilton, Connecticut $1.03B AUM 22.44% 1-Year Est. Return
MSA
Mason Street Advisors Milwaukee, Wisconsin $1.02B AUM 8.35% 1-Year Est. Return
TBA
Tower Bridge Advisors Conshohocken, Pennsylvania $1.04B AUM 23.66% 1-Year Est. Return

Samsara BioCapital's Q1 2022 Portfolio in Review

As of Q1 2022, Samsara BioCapital held 58 positions worth $397M, down 23% from $515M the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Samsara BioCapital deployed $42.4M of net new capital in Q1 2022, opening 7 new positions and adding to 4 existing holdings. Its largest new stake was Arcellx: 999,727 shares worth $14M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 96% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was SpringWorks Therapeutics, an estimated $4.64M trimmed.

  • Samsara BioCapital's largest Q1 2022 buy was Arcellx: 999,727 shares worth $14M.
  • Samsara BioCapital added most to Centessa Pharmaceuticals in Q1 2022, an estimated $3.87M increase.
  • Samsara BioCapital's biggest Q1 2022 reduction was SpringWorks Therapeutics, cutting an estimated $4.64M.
  • Samsara BioCapital's ten largest holdings make up 64% of its $397M portfolio in Q1 2022.
  • Samsara BioCapital opened 7 new positions and closed 1 in Q1 2022.
  • Samsara BioCapital's portfolio value fell 23% quarter-over-quarter to $397M.

Based on Samsara BioCapital's 13F filing for Q1 2022, filed 16 May 2022.